Callisto Pharmaceuticals Inc - Amended Statement of Ownership (SC 13G/A)
02 Mayo 2008 - 1:04PM
Edgar (US Regulatory)
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, DC 20549
_________________
SCHEDULE
13G
INFORMATION
STATEMENT PURSUANT TO RULES 13D-1 AND 13D-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)
1
|
Callisto
Pharmaceuticals Inc.
|
|
|
(Name of
Issuer)
|
|
Common
Shares
|
|
|
(Title of
Class of Securities)
|
|
April 18,
2008
|
|
|
(Date of
Event Which Requires Filing of this Statement)
|
Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:
Rule
13d-1(b)
Rule
13d-1(c)
Rule 13d-1(d)
_________________
1
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities of that section of the Act but shall be subject to
all other provisions of the Act (however,
see
the
Notes
.)
|
CUSIP No.
1312EM104
|
13G
|
Page 2 of 5 Pages
|
|
1)
|
Names of Reporting Persons
I.R.S. Identification Nos. of Above Persons (entities only)
RAB Special Situations (Master) Fund Limited
|
|
2)
|
Check the Appropriate Box if a Member of a Group
(See Instructions)
(a)
(b)
|
|
4)
|
Citizenship or Place of Organization
Cayman Islands
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
(5)
|
Sole Voting Power
20,903,733*
|
|
(6)
|
Shared Voting Power
0
|
|
(7)
|
Sole Dispositive Power
20,903,733*
|
|
(8)
|
Shared Dispositive Power
0
|
|
9)
|
Aggregate Amount Beneficially Owned by Each
Reporting Person
20,903,733*
*The reporting person owns 603,493 shares of common stock of the issuer, 500,000
Series B Preferred shares, which may be converted into 10,000,000 common shares,
and warrants exercisable to acquire an additional 10,300,240 shares of common
stock. The Series B preferred shares warrants are not convertible into common
shares if, as a result of a conversion or exercise, the holder would then become a
“ten percent beneficial owner” of the issuer’s common stock, as
defined in Rule 16a-2 under the Securities Exchange At of
1934.
1
|
|
10)
|
Check If the Aggregate Amount in Row (9) Excludes
Certain Shares
(See Instructions)
[ ]
|
|
11)
|
Percent of Class Represented by Amount in Row
(9)
Up to 9.9999%**
**The percentages used herein are calculated based upon 47,218,161 outstanding
shares as of March 25, 2008, plus 20,300,240 common shares in aggregate underlying
convertible securities which are beneficially owned by the reporting persons and
included pursuant to Rule 13d-3(d)(1)(i) of the Act.
|
|
12)
|
Type of Reporting Person (See Instructions)
CO
|
1
The Schedule 13G filed by the reporting person
on February 14, 2008, erroneously reported the number of shares resulting from conversion
of the Series B preferred shares as 1,000,000. Since December 31, 2007, the reporting
person has disposed of 104,800 common shares of the issuer.
|
CUSIP No.
1312EM104
|
13G
|
Page 3 of 5 Pages
|
|
Item 1 (a)
|
Name of Issuer:
|
|
|
Callisto Pharmaceuticals
Inc.
|
|
Item
1 (b)
|
Address of
Issuer’s Principal Executive Offices:
|
|
|
420 Lexington Avenue, Suite
1009
New York, New York 10170
|
|
Item 2 (a)
|
Name of Person
Filing:
RAB Special
Situations (Master) Fund Limited
|
|
Item 2 (b)
|
Address of
Principal Business Office or, if none, Residence:
|
|
|
RAB Special
Situations (Master) Fund Limited
P.O. Box 908 GT
Walker House Mary Street
George Town, Cayman Islands
|
|
Item 2 (c)
|
Citizenship:
Cayman Islands
|
|
Item 2 (d)
|
Title of Class
of Securities:
Common Shares
|
|
Item 2 (e)
|
CUSIP
Number:
|
|
|
1312EM104
|
|
Item 3.
|
If this statement is filed
pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is
a:
|
|
|
(a)
|
|
Broker or
dealer registered under Section 15 of the Act.
|
|
|
(b)
|
|
Bank as defined in Section
3(a)(6) of the Act.
|
|
|
(c)
|
|
Insurance company as
defined in Section 3(a)(19) of the Act.
|
|
|
(d)
|
|
Investment company
registered under Section 8 of the Investment Company Act.
|
|
|
(e)
|
|
An investment adviser in
accordance with Rule 13d-1(b)(1) (ii)(E);
|
|
|
(f)
|
|
An employee benefit plan or
endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
|
|
|
(g)
|
|
A parent holding company,
in accordance with Rule 13d-1(b)(ii)(G);
|
|
|
(h)
|
|
A savings association as
defined in Section 3(b) of the Federal Deposit Insurance Act;
|
|
|
(i)
|
|
A church plan that is
excluded from the definition of an investment company under section 3(c)(14) of the
Investment Company Act of 1940;
|
|
|
(j)
|
|
Group, in accordance with
Rule 13d-1(b)(1)(ii)(J).
|
|
|
|
|
|
|
|
|
|
If this statement is filed
pursuant to Rule 13d-1(c), check this box.
|
|
CUSIP No.
1312EM104
|
13G
|
Page 4 of 5 Pages
|
|
Item 4.
|
Ownership.
|
|
|
Provide the following
information regarding the aggregate number and percentage of the class of
securities identified in Item 1.
|
|
|
(a)
|
Amount
beneficially owned:
|
|
|
|
See Item 9 on the cover
page
|
|
|
(b)
|
Percent of
Class:
|
|
|
|
See Item 11 on the cover
page
|
|
|
(c)
|
Number of
shares as to which such person has:
(i) Sole power to vote or to direct the
vote:
(ii) Shared power to vote or direct the
vote:
(iii) Sole power to dispose or to direct the disposition
of:
(iv) Sole power to dispose or to direct the disposition
of:
See Items 5-8 on cover page
|
|
Item 5.
|
Ownership of Five Percent or
Less of a Class.
|
|
|
If the
statement is being filed to report the fact that as of the date hereof the
reporting person has ceased to be the beneficial owner of more than five percent of
the class of securities, check the following
|
|
Item 6.
|
Ownership of More than Five
Percent on Behalf of Another Person.
|
|
|
N/A
|
|
Item 7.
|
Identification and
Classification of the Subsidiary Which Acquired the Security Being Reported on by
the Parent Holding Company or Control Person.
|
|
|
N/A
|
|
Item 8.
|
Identification and
Classification of Members of the Group.
N/A
|
|
Item 9.
|
Notice of Dissolution of
Group.
N/A
|
|
CUSIP No.
1312EM104
|
13G
|
Page 5 of 5 Pages
|
|
Item 10.
|
Certification.
|
|
|
By
signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not held for the purpose of
or with the effect of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.
|
|
RAB Special
Situations (Master) Fund Limited
by Benjamin Hill and Fraser McGee
Authorised signatories for RAB Capital plc
for and on behalf of
RAB Special Situations (Master) Fund Limited
/s/
Benjamin
Hill
(Signature)
/s/
Fraser
McGee
(Signature)
|
Callisto (AMEX:KAL)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Callisto (AMEX:KAL)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
Real-Time news about Callisto Pharmaceuticals, (American Stock Exchange): 0 recent articles
Más de Callisto Pharmaceuticals Inc Artículos de Noticias